Albiruni Abdul Razak

Author

Also Known As

A. A. Razak, A. Abdul Razak, A. Razak, A.A. Razak, Albiruni A Razak, Albiruni A. R. Razak, Albiruni A. RAZAK, Albiruni A. Razak, Albiruni A.R. Razak, Albiruni Abdul Razak

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Toronto University Health Network Ontario Institute for Cancer Research Institut Gustave Roussy

About

Albiruni Abdul Razak is an author at Princess Margaret Cancer Centre specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	834
2	Pathology	6	6	652
3	Immunology	4	4	554
4	Health Sciences	2	2	125
5	Gastroenterology	1	1	29

Albiruni Abdul Razak

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab Scott V. Bratman, S.Y. Cindy Yang, Marco Iafolla, Nature Cancer Prognostic BiomarkersTumor Dna AnalysisMedicineBiomarker TargetImmunology	2020	466
Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status Shao Hui Huang, John Waldron, Michael Milosevic, Cancer	2014	170
Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities Yada Kanjanapan, Daphne Day, Lisa Wang, Cancer	2019	140
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity S.Y. Cindy Yang, Scott Lien, Ben X. Wang, Nature Communications	2021	125
Temporal Nodal Regression and Regional Control After Primary Radiation Therapy for N2-N3 Head-and-Neck Cancer Stratified by HPV Status Shao Hui Huang, Brian O’Sullivan, Wei Xu, International Journal of Radiation OncologyBiologyPhysics Adaptive RadiotherapyTemporal Nodal RegressionRegional ControlRadiation TherapyMedicine	2013	110
Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma Anna Spreafico, Shao Hui Huang, Wei Xu, European Journal of Cancer Advanced HeadMedicinePathologyNeck PathologyHead And Neck Cancer	2016	83
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Annals of Oncology	2022	74
An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors Kirsty Taylor, Helen Loo Yau, Ankur Chakravarthy, Journal for ImmunoTherapy of Cancer	2020	66
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors Iván Díaz-Padilla, Hal W. Hirte, Amit M. Oza, Investigational New Drugs	2013	56
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hans Gelderblom, Vivek A. Bhadri, Silvia Stacchiotti, The Lancet Surgical OncologyMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2024	54

Page 1